NCT01222611

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Fundacion SEIMC-GESIDA · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study examines the impact of fosamprenavir as part of an ART on virological, immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected subjects. Fosamprenavir could have a direct or immune-mediated activity against HCV. If this is shown to be true, changes in HCV viral load or biological characteristics could be demonstrated.

Conditions

• Chronic HIV Infection
• HCV Coinfection

Interventions

Type	Name	Description
DRUG	Fosamprenavir	HAART including fosamprenavir boosted with ritonavir

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-06-01
• Completion: 2013-06-01
• First posted: 2010-10-18
• Last updated: 2014-05-30

Locations

6 sites across 1 country: Spain